Last edition
News about Clinical Trials
In the past 12 months, Velocity has randomized 25,000 patients into phase II and III studies in the US. The tech investments will enable Velocity to be more efficient in managing studies, identifying patients for studies, and increasing the frequency of participation in studies
Clinical Trials | 16/02/2022 | By Darshana | 487
Drug Technical Advisory Board suggests recommendations under clinical trial to DCGI
DTAB has recommended that the proposed provisions for grant of licence to manufacture and stock of new drug which is under clinical trial is considered appropriate for drugs/vaccines being developed for emergency/life-saving/COVID-19 and similar such conditions of public health importance
Clinical Trials | 14/02/2022 | By Darshana | 640
Serum's proposal to manufacture vaccine against omicron for test and analysis, gets a DGCI nod
The Drugs Controller General of India (DCGI) has approved Serum Institute of India?s proposal to manufacture a vaccine against omicron variant of coronavirus for examination, test and analysis.
Clinical Trials | 09/02/2022 | By Darshana | 193
Biotron Limited, a company engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, announced that the company?s lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed
Clinical Trials | 29/11/2021 | By Darshana | 220
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners have collaborated to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialise Takeda's norovirus vaccine candidate
Clinical Trials | 03/08/2021 | By Darshana | 288
Final results from the head-to-head ELEVATE-RR phase III trial of AstraZeneca's Calquence (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults with previously treated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia
Clinical Trials | 08/06/2021 | By Darshana | 443
Novartis announced results from the pivotal phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001). The study evaluated tislelizumab in patients with unresectable recurrent locally advanced
Clinical Trials | 07/06/2021 | By Darshana | 349
CSIR and Laxai Life Sciences initiate clinical trials of drug niclosamide for Covid-19 treatment
CSIR in collaboration with Laxai Life Sciences Pvt. Ltd., has initiated phase-II clinical trial with anti-helminitic drug niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of niclosamide for the treatment of hospitalized Covid-19 patients.
Clinical Trials | 07/06/2021 | By Darshana | 505
MSN Labs initiates phase III trial of molnupiravir to treat Covid-19 in India
MSN Laboratories, a leading integrated pharmaceutical company, has announced that it is now initiating phase III clinical trial of molnupiravir capsules for the treatment of Covid-19 in India
Clinical Trials | 25/05/2021 | By Darshana | 286
Merck announced V114, the company's investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 phase 3 pediatric clinical program. These data support the potential use of V114 in healthy infants who may have previously started a pneumococcal vaccination series
Clinical Trials | 22/05/2021 | By Darshana | 197
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy